FACSDiscover A7 — commercial launch and evidence limits
Summary
Waters announced FACSDiscover A7 commercial availability in September 2026. The research-use-only spectral analyzer combines automated instrument setup/QC and downstream spectral analysis. Reported reproducibility figures come from manufacturer testing, not independent clinical assay validation.
Source Date
Source checked
Event Type
Event Date
September 14, 2026
Geography
Global launch announcement; local availability may vary
Commercial Regulatory Status
Commercially available, RUO. No CE-IVD or FDA diagnostic authorization inferred.
Related CFCM Topics
Knowledge: Spectral Cytometry; Academy: Panel Setup, QC and Validation; Tools: Cytometer Comparator; Evidence: reproducibility; Intelligence: Technology Radar
Category
Primary source
Read the source →Facts supported by cited sources
Waters announced the FACSDiscover A7 spectral cell analyzer for research workflows. FACSTruQ supports automated instrument setup and QC, and SpectralFX supports spectral data analysis.
Claims Requiring Caution
Reported CV below 10% across more than 50 fluorochromes is manufacturer-generated. Instrument repeatability does not establish interlaboratory clinical assay transferability or MRD performance.
Why It Matters
CFCM analysis: A cytometer may achieve stable optical performance while sample preparation, staining, spectral unmixing, analysis and rare-event detection still vary between laboratories.
CFCM explainer — conceptual workflow: Sample and antibody panel → FACSTruQ setup/QC → spectral acquisition → SpectralFX unmixing → gating and analysis → independent assay validation. This is a conceptual diagram, not a claim of validated clinical performance.
An announcement is not proof of availability or authorisation. Interpret status within the stated jurisdiction and evidence boundary.
Editor and independence disclosure →